Status: Recruiting
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
Participants needed: 398
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Hummingbird BioscienceUpdated: May 27, 2026Locations: 20
Eligibility criteria
Ability to understand and be willing to sign an informed consent form [+9]
Prior treatment with HMBD-001, docetaxel, cetuximab or any other agent that targ... [+14]